Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
TBD Cabozantinib Withdrawn
Admelog Insulin lispro Cancelled
Beleodaq Belinostat Withdrawn
Blincyto Blinatumomab Withdrawn
Xeljanz tofacitinib Cancelled
Erbitux Cetuximab Cancelled
Ogivri Trastuzumab Withdrawn
Zytiga Abiraterone Withdrawn
TBC filgrastim Cancelled
TBD Entrectinib Withdrawn